Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm clinical trial, then an extension phase of AVT02 administered with a prefilled syringe

References

• Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritisclassification criteria: an American college of rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum . 2010;62(6):2569–2581.
   PubMedGoogle Scholar
• Hsieh P-H, Wu O, Geue C, et al. Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era. Ann Rheum Dis. 2020;79(6):771–777.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Humira prescribing information 2021.
   Google Scholar
• European Medicines Agency. Humira summary of product characteristics 2021.
   Google Scholar
• van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 2006;54(4):1063–1074.
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with Adalimumab plus methotrexate versus methotrexate alone or Adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26–37.
   PubMed Web of Science ®Google Scholar
• Nash P, Vanhoof J, Hall S, et al. Randomized crossover comparison of injection site pain with 40 mg/0.4 or 0.8 mL Formulations of adalimumab in patients with rheumatoid arthritis. Rheumatol Ther. 2016;3(2): 257–270.
   PubMed Web of Science ®Google Scholar
• Bergman M, Patel P, Chen N, et al. Evaluation of adherence and persistence differences between adalimumab citrate-free and citrate formulations for patients with immune-mediated diseases in the United States. Rheumatol Ther. 2021;8(1): 109–118.
   PubMed Web of Science ®Google Scholar
• Rekaya N, Vicik SM, Hulesch BT, et al. Enhancement of an auto-injector device for self-administration of etanercept in patients with rheumatoid arthritis confers emotional and functional benefits. Rheumatol Ther. 2020;7(3):537–552.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Guidance for industry rheumatoid arthritis: developing drug products for treatment -Draft guidance 2013 [Internet] [ cited 2022 May 06]. Available from: https://www.fdanews.com/ext/resources/files/archives/62813-01/06-07-13-RA.pdf.
   Google Scholar
• US Food and Drug Administration. Bioanalytical method validation. guidance for industry [Internet] [ cited 2022 June 01]. Available from: https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf.
   Google Scholar
• European Medicines Agency. Guideline on bioanalytical method validation [Internet] [ cited 2022 June 01]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf.
   Google Scholar
• Marini JC, Anderson M, Cai X-Y, et al. Systematic verification of bioanalytical similarity between a biosimilar and a reference biotherapeutic: committee recommendations for the development and validation of a single ligand-binding assay to support pharmacokinetic assessments. AAPS J. 2014;16(6):1149–1158.
   PubMed Web of Science ®Google Scholar
• Civoli F, Kasinath A, Cai X-Y, et al. Recommendations for the development and validation of immunogenicity assays in support of biosimilar programs. AAPS J. 2019;22(1):7.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Immunogenicity testing of therapeutic protein products - developing and validating assays for anti-drug antibody detection. Guidance for industry [Internet] [ cited 2022 June 1]. Available from: https://www.fda.gov/media/119788/download.
   Google Scholar
• European Medicines Agency. Guideline on Immunogenicity assessment of therapeutic proteins [Internet] [ cited 2022 June 01]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf.
   Google Scholar
• Wynne C, Schwabe C, Lemech C, et al. A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST). Expert Opin Investig Drugs. 2022;31(9):965–976.
   Web of Science ®Google Scholar
• Feldman SR, Reznichenko N, Pulka G, et al. Efficacy, safety and immunogenicity of avt02 versus originator adalimumab in subjects with moderate to severe chronic plaque psoriasis: a multicentre, double-blind, randomised, parallel group, active control, Phase III study. BioDrugs. 2021;35(6): 735–748.
   PubMed Web of Science ®Google Scholar
• Wynne C, Stroig H, Dias R, et al. Multi-center, randomized, open-label, 2-arm parallel study to compare the pharmacokinetics, safety and tolerability of AVT02 administered subcutaneously via prefilled syringe or autoinjector in healthy adult volunteers. Ann Rheum Dis. 2022;81(Suppl 1):1891–1892.
   Google Scholar
• ClinicalTrials.gov. PK, safety and tolerability study of AVT02 (Adalimumab) pre-filled syringe (PFS) vs, AVT02 autoinjector (AI) [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT03983876.
   Google Scholar
• Gerosa M, De Angelis V, Riboldi P, et al. Rheumatoid Arthritis: a Female Challenge. Women’s Health. 2008;4(2):195–201.
   PubMedGoogle Scholar
• Erol AM, Ceceli E, Uysal Ramadan S, et al. Effect of rheumatoid arthritis on strength, dexterity, coordination and functional status of the hand: the relationship with magnetic resonance imaging findings [Effect of rheumatoid arthritis on strength, dexterity, coordination and functional status of the hand: the relationship with magnetic resonance imaging findings]. Acta Reumatol Port. 2016;41(4):328–337.
   PubMed Web of Science ®Google Scholar
• Da Sferra Silva G. De Almeida Lourenço M, De Assis MR. Hand strength in patients with RA correlates strongly with function but not with activity of disease. Adv Rheumatol. 2018;58:20.
   PubMedGoogle Scholar
• van den Bemt BJF, Gettings L, Domańska B, et al. A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience. Drug Deliv. 2019 Dec;26(1):384–392.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Biosimilar product regulatory review and approval.
   Google Scholar
• European Medicines Agency. Biosimilars in the EU.
   Google Scholar
• Martinec R, Pinjatela R, Balen D. Quality of life in patients with rheumatoid arthritis-a preliminary study. Acta Clin Croat. 2019;58(1):157–166.
   PubMed Web of Science ®Google Scholar
• Katchamart W, Narongroeknawin P, Chanapai W, et al. Health-related quality of life in patients with rheumatoid arthritis. BMC Rheumatol. 2019;3:34.
   PubMedGoogle Scholar
• Cohen S, Genovese MC, Choy E, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis. 2017;76(10):1679–1687.
   PubMed Web of Science ®Google Scholar
• Cohen SB, Alonso-Ruiz A, Klimiuk PA, et al. Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study. Ann Rheum Dis. 2018;77:914–921.
   PubMed Web of Science ®Google Scholar
• Papp K, Bachelez H, Costanzo A, et al. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2017;177(6):1562–1574.
   PubMed Web of Science ®Google Scholar
• Burmester G-R, Kivitz AJ, Kupper H, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis. 2015;74(6):1037–1044.
   PubMed Web of Science ®Google Scholar
• Ghil J, Zielińska A, Lee Y. Usability and safety of SB5 (an adalimumab biosimilar) prefilled syringe and autoinjector in patients with rheumatoid arthritis. Curr Med Res Opin. 2019;35(3):497–502.
   PubMed Web of Science ®Google Scholar
• Karlsdottir K, Gunnarsdottir AI, Grondal G, et al. A patients’ perspective towards the injection devices for humira® and imraldi® in a nationwide switching program. Front Med (Lausanne). 2022;9:799494.
   PubMed Web of Science ®Google Scholar